You are here: Industry Insights > TNBC

News List

Gilead gets US FDA nod for Trodelvy to treat metastatic triple-negative breast cancer expresspharma
April 09, 2021
Trodelvy significantly reduced the risk of death by 49 per cent compared with single-agent chemotherapy in the Phase 3 ASCENT Study.
EMA validates Gilead Sciences’ application for breast cancer therapy pharmaceutical-business-review
March 31, 2021
The European Medicines Agency (EMA) has validated Gilead Sciences’ marketing authorization application (MAA) for sacituzumab govitecan-hziy (SG) to treat advanced breast cancer.
FDA casts doubt on clinical meaningfulness of Merck’s Keytruda trial data pharmaceutical-technology
February 09, 2021
The US Food and Drug Administration (FDA) has cast doubt on the results from Merck’s KEYNOTE-522 trial of Keytruda (pembrolizumab) submitted to support its expanded label in treating triple-negative breast cancer (TNBC).
Researchers identify existing drug’s potential for triple negative breast cancer pharmatimes
January 29, 2021
Researchers at The Institute of Cancer Research, London (ICR) have identified an already approved breast cancer drug which could have promise in the treatment of triple negative breast cancer (TNBC).
HistoIndex Explores the Clinical Utility of Stain-free AI Digital Pathology Platform in 388 Patients with Triple-Negative Breast Cancer (TNBC) prnasia
January 25, 2021
HistoIndex's stain-free AI digital pathology platform, incorporating Second Harmonic Generation (SHG), holds promise as a quantitative tool in the assessment of morphological and architectural changes in collagen fibers within the tumor-stromal ...
PhoenixMD Announces First Patient Dosed in Triple Negative Breast Cancer Trial americanpharmaceuticalreview
December 11, 2020
Phoenix Molecular Designs (PhoenixMD) announced the first patient has been dosed in their Phase 1b clinical trial of PMD-026.
FDA approves Merck’s Keytruda with chemotherapy to treat breast cancer pharmaceutical-technology
November 17, 2020
Merck (MSD) has secured approval from the US Food and Drug Administration (FDA) for its Keytruda in combination with chemotherapy for treating patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumours ..
Oncolytics Biotech Doses First Patient in Pelareorep-anti-PD-1 Study for Breast Cancer americanpharmaceuticalreview
August 27, 2020
Oncolytics Biotech® announced the first patient has been dosed in the Company's investigator-sponsored phase 2 study of pelareorep-anti-PD-1 combination therapy in unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer pharmaceutical-business-review
July 06, 2020
Daiichi Sankyo Company announced the first patient with triple negative breast cancer (TNBC) has been dosed in the ongoing phase 1 study assessing DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC).
Roche's Tecentriq shows promise in early triple-negative breast cancer pharmatimes
June 22, 2020
Roche's Tecentriq (atezolizumab) in combination with chemotherapy has improved treatment response in people with early triple-negative breast cancer (TNBC), raising hopes for a new therapeutic option for the condition.

Previous page 1 2 3 Next page